Published in Vaccine Weekly, May 8th, 2002
Affitech secured an exclusive option to Troybodies from the technology's inventors at the University of Oslo and the Norwegian National Hospital. This option will now be converted to an exclusive worldwide licence with unrestricted sublicense rights. As part of the option agreement, Affitech will enter into a research and development plan with the University of Oslo on cancer and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.